# Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/alectinib-versus-crizotinib-in-patients-with-alk-positive-non-small-cell-lung/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Toyoaki Hida,Hiroshi Nokihara,Masashi Kondo,Young Hak Kim,Koichi Azuma,Takashi Seto,Yuichi Takiguchi,Makoto Nishio,Hiroshige Yoshioka,Fumio Imamura,Katsuyuki Hotta,Satoshi Watanabe,Kōichi Goto,Miyako Satouchi,Toshiyuki Kozuki,Takehito Shukuya,Kazuhiko Nakagawa,Tetsuya Mitsudomi,Nobuyuki Yamamoto,T. Asakawa,Ryoichi Asabe,Tomohiro Tanaka,Tomohide Tamura |
| Citations | 921 |
| DOI | 10.1016/s0140-6736(17)30565-2 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2613260339 |
| PMID | 28501140 |
| Type | article |
| Year | 2017 |

## Paper authors

- [Nobuyuki Yamamoto](https://scholariq.org/researchers/nobuyuki-yamamoto/)
- [Kōichi Goto](https://scholariq.org/researchers/koichi-goto/)

## Paper journal

- [The Lancet](https://scholariq.org/journals/the-lancet/)

## Paper primary topic

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)

## Paper topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.